Allogene Therapeutics

General Information
Business:

 

We are a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. We are developing a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells. Our engineered T cells are allogeneic, meaning they are derived from healthy donors for intended use in any patient, rather than from an individual patient for that patient’s use, as in the case of autologous T cells. We believe this key difference will enable us to deliver readily available treatments faster, more reliably, at greater scale, and to more patients.

Industry: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)
Employees: 70
Founded: 2017
Contact Information
Address 210 East Grand Avenue, South San Francisco, CA 94080, US
Phone Number (415) 640-5325
Web Address http://www.allogene.com
View Prospectus: Allogene Therapeutics
Financial Information
Market Cap $2074.1mil
Revenues $0 mil (last 12 months)
Net Income $-0.1 mil (last 12 months)
IPO Profile
Symbol ALLO
Exchange NASDAQ
Shares (millions): 18.0
Price range $18.00 - $18.00
Est. $ Volume $324.0 mil
Manager / Joint Managers Goldman Sachs/ J.P. Morgan/ Cowen/ Jefferies
CO-Managers -
Expected To Trade: 10/11/2018
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change